Given that high Lp-PLA2 activity is a hallmark of metabolic-dysfunction-associated steatotic liver disease (MASLD), we aimed to investigate whether it contributes additional CVD risks when MASLD coexists with T2DM. The gene discussed is PLA2G7; the disease is type 2 diabetes mellitus.